Table 4.
Maximum dermal assessment scores from removal of patch through termination
| Score (0 to 7)a | L.M.X.4 (n = 39) | Topicaine (n = 38) | Betacaine (n = 40) |
|---|---|---|---|
| 0, n (%) | 10 (26) | 10 (26) | 14 (35) |
| 1, n (%) | 10 (26) | 10 (26) | 11 (28) |
| 2, n (%) | 15 (38) | 17 (45) | 13 (33) |
| 3, n (%) | 2 (5) | 0 | 1 (3) |
| 4, n (%) | 1 (3) | 1 (3) | 1 (3) |
| 5, n (%) | 1 (3) | 0 | 0 |
| 6, n (%) | 0 | 0 | 0 |
| 7, n (%) | 0 | 0 | 0 |
| P valueb | – | 0.916 | 0.284 |
a
Notes: 0 = no evidence of irritation; 1 = minimal erythema, barely perceptible; 2 = definite erythema, readily visible; minimal edema or minimal papular response; 3 = erythema and papules; 4 = definite edema; 5 = erythema, edema, and papules; 6 = vesicular eruption; 7 = strong reaction spreading beyond test site.
b
P value was computed from a Cochran–Mantel–Haenszel test comparing distribution of maximum score (0, 1, ≥2) between the L.M.X.4 group and the other two topical anesthetics groups.